Vikas Gupta, Site Group Lead, Leukemia Program at Princess Margaret Cancer Centre, shared a post on X:
“Bench to bedside story – Chan Lab at Princess Margaret – Guillaume Richard-Carpentier, Gupta Gopila, Aniket Bankar, The Princess Margaret Cancer Foundation- Enasidenib plus venetoclax in patients with IDH2-mutated relapsed/refractory AML/MDS (ENAVEN-AML): a multicentre, single-arm, phase 1b/2 trial.”
Title: Enasidenib plus venetoclax in patients with IDH2-mutated relapsed or refractory acute myeloid leukaemia or myelodysplastic syndrome (ENAVEN-AML): a multicentre, single-arm, phase 1b/2 trial
Authors: Guillaume Richard-Carpentier, Gopila Gupta, Charina Koraksic, Severine Cathelin, Lisa Wang, Aniket R. Bankar, Marta B. Davidson, Vikas Gupta, Dawn C. Maze, Mark D. Minden, Tracy Murphy, Aaron D. Schimmer, Andre C. Schuh, Hassan Sibai, Karen W. L. Yee, Courtney D. DiNardo, Joseph M. Brandwein, Caroline J. McNamara, Steven M. Chan
Read the full article on Sosido.
More posts featuring Vikas Gupta on OncoDaily.